OncoSec seeks to deliver safer and more effective cancer treatments that can provide long-term benefits for patients who have limited or no available treatment options. Its technology combines TAVO™ (tavokinogene telseplasmid), an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12) designed to achieve targeted and sustained delivery of IT IL-12. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including preliminary data in a registration directed Phase 2b trial KEYNOTE-695 for anti-PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple-negative breast cancer (mTNBC).